Ligand Pharmaceuticals News

4: Statement of changes in beneficial ownership of securities-Director Aryeh Jason

May 3 06:10

4: Statement of changes in beneficial ownership of securities-Director KOZARICH JOHN W

Apr 27 06:39

DEFA14A: Others

Apr 26 02:44

ARS: Annual Report to Security Holders

Apr 26 02:44

DEF 14A: Definitive information statements

Apr 26 02:44

8-K: Current report

Apr 20 04:11

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Davis Todd C

Mar 28 05:50

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Sabba Stephen L

Mar 8 02:30

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Aryeh Jason

Mar 7 06:31

Ligand Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Mar 6 07:14

Ligand Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 2 05:12

Ligand Pharmaceuticals | 10-K: Annual report

Mar 1 11:53

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Reardon Andrew

Mar 1 07:54

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Korenberg Matthew E

Mar 1 07:54

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Espinoza Octavio

Mar 1 07:54

Ligand Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Davis Todd C

Mar 1 07:54

Ligand Pharmaceuticals | 144/A: Others

Mar 1 05:54

Ligand Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Feb 29 07:09

Ligand Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Feb 29 06:54

Ligand Pharmaceuticals | 8-K: Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27 20:25